Latest News: Proscia profiled in KLAS Emerging Company Spotlight.DOWNLOAD THE REPORT

Proscia Raises $23M in Series B Funding Led by Scale Venture Partners

By Author Proscia | December 1, 2020

Investment to accelerate adoption of digital pathology, transforming 150-year-old standard of care for cancer diagnosis

PHILADELPHIA – December 1, 2020 – Proscia®, a leading provider of digital and computational pathology solutions, has secured $23 million in Series B funding led by Scale Venture Partners, with participation from Hitachi Ventures, the strategic corporate venture capital arm of Hitachi, Ltd., bringing its funding total to $35 million. The company will use the investment to accelerate its global growth and strengthen its position of leadership in transforming cancer research and diagnosis at a time when demand for modernizing pathology is higher than ever.

The practice of pathology sits at the core of biomedical research and cancer diagnosis. Until recently, this practice has remained largely unchanged in its 150-year history, depending solely on the human eye recognizing patterns in tissue under the microscope. With its Concentriq® software platform, Proscia is accelerating the transformation to digital pathology, which centers around high-resolution images of tissue biopsies, as the new standard of care. Concentriq combines enterprise scalability with powerful AI applications to help laboratories, health systems, and life sciences companies unlock new insights, accelerate breakthroughs, and improve patient outcomes.

“Digitization has swept through almost every domain of healthcare, and we are now seeing its revolutionary impact on pathology,” said Alexander Niehenke, Partner at Scale Venture Partners. “Proscia is a high-growth company with a unique platform-plus-AI approach that is enabling it to capitalize on a multi-billion-dollar market opportunity. We’re excited to be a part of Proscia’s success as it expands its leadership position in pathology’s shift from analog to digital.”

The infusion of capital will enable Proscia to continue to meet growing demand for digital pathology across research and diagnostics. The company will use the funds to accelerate commercial expansion, ramping up its global sales, marketing, and support teams. Proscia will also further drive pathology’s data-driven future by expanding its data assets and AI application portfolio, building off of the initial success of its DermAI™ application. The investment will additionally advance Proscia’s regulatory strategy to secure FDA clearance, drawing on the foundation that the company has established with its CE Mark and MDSAP certification.

Since closing its Series A round in 2018, Proscia has amassed a customer base of laboratory titans and digital pathology pioneers as well as 10 of the top 20 pharmaceutical companies. This includes Johns Hopkins School of Medicine and the Joint Pathology Center (JPC), the premiere pathology reference center for the U.S. government. JPC selected Concentriq to drive a complete modernization of its pathology practice and digitize the world’s largest human tissue repository of over 55 million slides, unleashing a transformative wave of biomedical research. Proscia also recently established a Computational Pathology Center of Excellence with University Medical Center (UMC) Utrecht, one of the first organizations in the world to implement digital pathology. As part of this collaboration, UMC Utrecht will deploy Proscia’s AI applications into its high-throughput workflows leveraging Concentriq.

“We are excited for this next milestone in our journey,” said David West, CEO of Proscia. “Over the past few years, we have battle tested Concentriq at leading organizations and demonstrated the unprecedented potential of AI. In welcoming Scale Venture Partners and Hitachi Ventures to the Proscia team, we are better positioned than ever before to drive a transformation that will impact millions of cancer patients and their families.”

Proscia’s commercial traction comes amid a surge in digital pathology adoption. Laboratories have increasingly shifted to digital to overcome the manual and subjective nature of the traditional standard of care and keep pace with the rising cancer burden. In the U.S. alone, pathologists have faced a 42% rise in diagnostic workload over the last decade, a challenge that will continue to intensify as the total number of cancer cases is projected to increase by 55% by 2030. Recently, laboratories have been implementing digital pathology to maintain operations during the COVID-19 pandemic, as digitization is the only means by which they can continue to serve patients.

“Digital pathology is quickly becoming the expected standard of diagnosis,” said Steve Holloway, Company Director & Principal Analyst at Signify Research. “The global pandemic has exacerbated longstanding pressures, accelerating adoption. This market has now crossed an inflection point, with a critical mass of digital laboratories creating the momentum for more widespread implementation of digital pathology and augmentation by artificial intelligence.”

Proscia was represented by Troutman Pepper in connection with the Series B financing.

Learn More

About Proscia
Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team of technologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. For more information, visit

Our website uses cookies. By using this site, you agree to its use of cookies.